StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Ziopharm Oncology (ZIOP) Reports First Patient Enrollment in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO
June 28, 2018 4:02 PM
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) today announced that it has enrolled the first patient in its Phase 1 clinical trial ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Intrexon (XON) Prices 7.48M Share Common Offering at $13.37/Sh
June 29, 2018 6:08 AM
Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
June 28, 2018 4:01 PM